Acomplia aka Zimulti - The latest breakthrough for obesity and smoking cessation

Acomplia / Zimulti contains Rimonabant, the long awaited breakthrough drug by Sanofi for the treatment of obesity and smoking cessation.

Acomplia represents one of the latest and indeed a most novel method for controlling body weight. Acomplia operates by being a cannabinoid receptor antagonist. This means that Acomplia prevents the normal action of endogenous cannabinoid in the brain from stimulating the so-called CB1 receptors. It would appear that these receptors stimulate appetite and therefore when they are “subdued” so is the need to eat.

The clinical trials that have been run over the past few years are impressive and have shown that these receptor sites may be responsible for more than just appetite, because the results show that Acomplia also aids people to stop smoking and even improves cardiovascular factors such as cholesterol ratios.

With specific regard to weight loss, the human trials have shown an average weight loss of 10% of bodyweight, most importantly that weight has remained off even up to 2-years later. Also importantly, it would appear that the majority of weight is actually lost from the difficult to lose area around the waist. The average figures from the trials show a loss of fat of 20 lbs (9 Kg) and 3 inches (8 cm) diameter taken off the waist.

Additional trials have been undertaken to help smokers kick the habit. Even here Acomplia has been successful, showing that persons using Acomplia have double the chance of quitting smoking for good, and perhaps importantly also helping those smokers from not gaining any weight once they stop smoking, (as it is often the case that smokers trying to quit substitute their cigarettes with food etc.).

On top of that, Acomplia has also been shown to improve HDL (good cholesterol) and triglyceride levels, showing benefit for diabetes and heart conditions.

Meanwhile, Acomplia has shown few and minor side effects in the clinical trials, some of which have been conducted continuously for 2-years. Side effects noted in the studies were mainly mild and transient consisting (in order of frequency) of nausea, dizziness, diarrhoea, vomiting, hypoglycaemia and anxiety.

The most beneficial doses noted in the trials have been 20 mg. daily.

Perhaps it is no wonder that Acomplia is expected to be a blockbuster drug now it is available in Europe.